Myocardial remodelling: Pharmacological targets

Expert Opinion on Investigational Drugs

Volumn 11, Issue 5, 2002, Pages 661-674

  Swynghedauw, Bernard ^a  

^a INSERM   (France)

Author keywords

Cardiac remodelling; Heart failure

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APOPTOSIS INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM SENSITIZER; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; INOTROPIC AGENT; ISOPRENALINE; LOOP DIURETIC AGENT; LOSARTAN; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; MILRINONE; N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE; NITRIC OXIDE DONOR; OMAPATRILAT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PIPERANOMETOZINE; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VASOPEPTIDASE INHIBITOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GYNECOMASTIA; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; LIFESPAN; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; APOPTOSIS; DRUG ANTAGONISM; DRUG EFFECT; FORWARD HEART FAILURE; GENE EXPRESSION; GENETICS; HEART CONTRACTION; HEART VENTRICLE REMODELING; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOPTOSIS; CARDIAC OUTPUT, LOW; GENE EXPRESSION; HUMAN; METALLOENDOPEPTIDASES; MYOCARDIAL CONTRACTION; NITRIC OXIDE DONORS; VENTRICULAR REMODELING; HUMANS;

EID: 0035999742     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.5.661     Document Type: Review

References (96)

1. Structural basis for heart failure. ventricular remodeling and its pharmacological inhibition
2. Molecular mechanisms of myocardial remodeling
3. Evolutionary Medicine
4. The effect of pressure of flow stress on right ventricular protein synthesis in the face of constant and restricted coronary perfusion
5. Nonsynchronous accumulation of alpha-skeletal actin and beta-myosin heavy chain mRNAs during early stages of pressure-overloade induced cardiac hypertrophy demonstrated by in situ hybridization
6. Aortic perfusion pressure as early determinant of beta-isomyosin expression perfused hearts
7. Cardiac mechanics and energetics: Chemomechanical transduction in cardiac muscle
8. Force velocity relationship in mammalian heart muscle
9. Increased myothermal economy of isometric force generation in compensated cardiac hypertrophy induced by pulmonary artery constriction in the rabbit - A characterization of heat liberation on normal and ventricular papillary muscles
10. Les effects du dinitrophenol sur I'hypertrophie cardiaque expérimentale du rat
11. Atrial natriuretic factor gene expression in rat ventricle during experimental hypertension in rat ventricle during experimental hypertension
12. Myosin isozymes redistribution in chronic heart overloading
13. +)-ATPase subunit mRNA and protein levels in hyperttrophied heart
14. Effects of moderate hypertension on cardiac function and metabolism in the rabbit
15. Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR
16. 2+-ATPase and calsequestrine genes in rat heart during ontogenic development and aging
17. + channel subunit mRNAs in ventricles of renovascular hypertensive rats
18. Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags
19. Altered gene patterns of gene expression in response to myocardial infarction
20. Application of the cDNA microarrays in determining molecular phenotype in cardiac growth, development and response to injury
21. The effects of elevated chronic loading on the action potential of mammalian myocardium
22. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure
23. Non-synchronous changes in myocardial collagen mRNA and protein during aging. Effect of DOCA-salt hypertension
24. Biology of the arterial wall
25. Cardiovascular regulatory mechanisms in advanced age
26. Collagen remodeling in myocardia of patients with diabetes
27. Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function
28. Left ventricular hypertrophy in obesity: Discrepancy between echo and electrocardiogram
29. Effects of low-flow ischemia on myocardial function and calcium-regulating proteins in adult and senescent rat hearts
30. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension
31. Coregulation of calcium channels and beta-adrenergic receptors in cultured chick embryo ventricular cells
32. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction
33. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts
34. The Spontaneously Hypertensive Rat as a model of the transition from compensated left ventricular hypertrophy to failure
35. Transition from compensatory hypertrophy to dilated failing left ventricles in Dahl salt-sensitive rats
36. Ventricular remodeling after myocardial infarction
37. What is wrong with positive inotropic drugs: Lessons from basic science and clinical trials
38. The effect of digoxin on mortality and morbidity in patients with heart failure
39. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces
40. Angiotensin II-forming pathways in normal and failing human hearts
41. Wound Healing in Cardiovascular Disease
42. Angiotensin-converting inhibitors
43. The beta-adrenergic system is modified in compensatory pressure cardiac overload in rats: Physiological and biochemical evidence
44. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure
45. A randomized trial of the angiotensin-receptor blocker Vasartan in chronic heart failure
46. Differential roles of AT1 and AT2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II
47. Angiotensin II Type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension
48. Evidence for angiotensin II Type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload
49. Inhibitory effect of angiotensin II Type 2 receptor on coronary arterial remodeling after aortic banding in mice
50. Beta1- and beta2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure
51. Beta1-adrenergic and muscarinic receptor densities in compensatory cardiac hypertrophy of the adult rat
52. The myocardial beta-adrenergic system in Spontaneously Hypertensive Heart Failure (SHHF) rats
53. Beta1- and beta2-adrenergic-receptor subpopulations in non failing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta1 receptor down-regulation in heart failure
54. ialpha-2 in human end-stage heart failure
55. Beta-blockers in heart failure: Recently completed and ongoing clinical trials
56. Long-term propranolol administration alters myocyte and ventricular geometry in rat hearts with and without infarction
57. Effects of oral milrinone on mortality in severe chronic heart failure
58. Therapeutic potential of G-protein coupled receptor kinases in the heart
59. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
60. Aldosterone and the heart: Towards a physiological function?
61. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation
62. Activation of cardiac aldosterone production in rat myocardial infarction
63. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin converting enzyme BMS-182657 in experimental hypertension and heart failure
64. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21 402 (RB105) in rats with experimental myocardial infarction
65. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice
66. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy
67. Effects of damaging endocardial surface on the mechanical performance of isolated cardiac muscle
68. NO and cardiac diastolic function
69. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension
70. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy
71. Frequency-dependent activation of a constitutives nitric oxide synthase and regulation of contractile function in adult rat ventricular myocytes
72. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure
73. The role of Tumor Necrosis Factor in the pathophysiology of heart failure
74. TNF-alpha and heart failure
75. Apoptosis in development
76. Safety and efficacy of a soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in patients with advanced heart failure
77. Meeting report-the LIDO, HOPE, MOXCON, and WASH studies
78. Growth factors and the extracellular matrix
79. Remodeling of the rat right and left ventricles in experimental hypertension
80. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations
81. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway
82. Matrix Metalloproteinase inhibition after myocardial infarction. A new approach to prevent heart failure
83. Matrix Metalloproteinase inhibition and the prevention of heart failure
84. Matrix Metalloproteinase inhibition during the developing of congestive heart failure. Effects on left ventricular dimensions and function
85. Apoptosis. Basic mechanisms and implications for cardiovascular disease
86. Apoptosis in pressure-overload-induced heart hypertrophy in the rat
87. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat
88. Apoptosis in myocytes in end-stage heart failure
89. Apoptosis in the failing heart
90. Apoptosis in Cardiac Biology
91. Apoptosis in target organs of hypertension
92. Nitric oxide as a bifunctional regulator of apoptosis
93. From bench to clinic with apoptosis-based therapeutic agents
94. Apoptosis: A potential target for discovering novel therapies for cardiovascular diseases
95. Caspase inhibition and limitation of myocardial infarct size: Protection against lethal reperfusion injury
96. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality